Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD
Official title: Exploring the Gut Microbiota and Dietary Contributors to Elevated Infant Fecal Calprotectin In Patients With Inflammatory Bowel Disease: A Pilot Study (CALINA-IBD)
Run by University of British Columbia · NCT07385807 · Data updated 2026-11-12
This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | Women only |
| Enrollment | 80 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 2 sites (Vancouver, British Columbia and 1 other locations) |
| Status | Recruiting |
| Started | March 20, 2026 |
| Main results expected | February 1, 2028 |
| Study ends | February 1, 2028 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT07385807 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant individuals aged 19 or older in the first, second, or early third trimester, with or without a documented diagnosis of IBD, who can provide serial biological samples and use a compatible smartphone app for dietary tracking are ideal candidates.
✕Probably not a fit
People who are under 19, not pregnant, or who have exclusionary conditions such as prior gastrointestinal cancer or bowel surgery, major immune-mediated diseases, recent probiotic use, or serious infection are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective longitudinal cohort that follows pregnant individuals with and without IBD and their infants through pregnancy and the first year of life. Participants provide serial fecal samples, one third-trimester vaginal swab, breastmilk, and dietary data via a smartphone app, and infants' fecal calprotectin (FCP) is measured as a marker of gut inflammation. The study compares microbiome compositions, human milk oligosaccharides (HMOs), and dietary patterns between IBD and non-IBD dyads and tracks associations with elevated infant FCP. Researchers will also attempt to build and validate a machine-learning model to predict high infant FCP at 1 year from maternal and infant microbiome and dietary data.
Why it matters
Potential benefit: If successful, the findings could identify maternal or infant microbiome and dietary factors that point to dietary or breastfeeding interventions to reduce infant gut inflammation and potentially lower later risk of allergy or IBD.
How similar studies have gone: Prior observational research has linked maternal microbiota and infant fecal calprotectin to later allergic and IBD risk, but combining detailed microbiome, HMO profiling, dietary data, and machine-learning prediction in pregnancy is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients * Pregnant individuals ≥19 years recruited during their first, second or early third trimester. * Own or have regular access to a smartphone compatible with the study smartphone application RXFood. IBD patients ● A documented IBD diagnosis (CD or UC) with active or quiescent disease. Non-IBD controls ● Absence of IBD. Exclusion Criteria: All patients * Inability to provide consent * Previous gastrointestinal cancer or bowel surgery * Renal disease * HIV/AIDS or other serious infection * Fetal chromosomal or structural abnormalities * Other immune-mediated diseases (e.g., multiple sclerosis, rheumatoid arthritis, primary sclerosing cholangitis) * Prebiotic, probiotic or postbiotic supplements in the month prior to first sample collection * Gastroenteritis during or 1 month before the first sample collection * Travel outside of Canada and the United States in the month prior to first sample collection IBD patients ● Pregnant individuals with active perianal or extra-intestinal disease in IBD
Where it's running
-
BC Children's Hospital Research Institute
Vancouver, British Columbia, Canada Recruiting -
BC Children's Hospital Research Institute
Vancouver, British Columbia, Canada Not yet recruiting
Study contacts
- Study coordinator: Genelle Lunken, PhD, RD
- Email: genelle.lunken@bcchr.ca
- Phone: 7782327016
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SMART-IBD app for teens with inflammatory bowel disease
This will test whether the SMART-IBD smartphone app helps adolescents ages 13–17 with IBD take their medicines and manage symptoms better than completing daily diaries alone.
-
Pregnancy in people with inflammatory bowel disease
This project will see if pregnancy changes how often women with IBD have disease flares by analyzing registry data from women who had pregnancies.
-
Infliximab plus the Crohn's Disease Exclusion Diet for children with Crohn's disease
This will test whether starting a Crohn's Disease Exclusion Diet at the same time as infliximab helps children with moderate-to-severe Crohn's disease get better and stay in remission.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.